BSG and hepatocellular carcinoma: Further, radiolabelled anti-EMMPRIN antibodies have been shown to be well-tolerated and decrease tumour recurrence in HCC patients, however the mechanism, whether due to blocking EMMPRIN function, enhancing delivery of radio-therapeutics or both, is unclear [308,309].